Modality
ERT
MOA
DLL3 ADC
Target
MALT1
Pathway
Complement
RBCTCL
Development Pipeline
Preclinical
Jan 2019
→ Aug 2031
PreclinicalCurrent
NCT04420429
2,998 pts·CTCL
2019-01→2031-08·Not yet recruiting
NCT05845670
455 pts·RB
2021-05→2025-10·Completed
3,453 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-165mo agoInterim· RB
2031-08-285.4y awayInterim· CTCL
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Not yet…
Preclinical
Complet…
Catalysts
Interim
2025-10-16 · 5mo ago
RB
Interim
2031-08-28 · 5.4y away
CTCL
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04420429 | Preclinical | CTCL | Not yet recr... | 2998 | LiverFat |
| NCT05845670 | Preclinical | RB | Completed | 455 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| ION-8812 | Ionis | Phase 1 | MALT1 |